A Debt-Free Pharma Powerhouse with Strong Growth, Global Reach & Chronic Care Dominance

Company Overview & Heritage Founded in 1935 in Mumbai, Cipla has evolved into one of India’s most respected pharmaceutical companies. The business spans generics, branded medicines, inhalation therapies, oncology, and over-the-counter (OTC) healthcare. With a presence in over 80 countries through 47 manufacturing units and a workforce of nearly 28,000, Cipla is the third-largest drugmaker in India and a staple of the Nifty 50 index. Financial Performance Snapshot Q4 FY25 (January–March 2025) Highlights: Revenue: ₹6,600–6,730 crore (+8–9% YoY) Net Profit: ~₹1,222 crore (+30% YoY) EBITDA: ₹1,538 crore, margin ~22.8%, up ~150 bps YoY Special mention: The company declared a final dividend of ~₹13 plus a special ₹3 dividend, celebrating its 90th anniversary. FY25 Annual Performance: Total Revenue: ₹27,550 crore (+8% YoY) Net Profit: ₹5,270 crore (+28–30%) EBITDA Margin: ~25.9% Key financial ratios: ROE: ~16.9%, above its 5-year average ~13.5% Interest Cost: Minimal—under 1% of revenues Employee Cost: ~17.5% of revenue EPS: ₹65–66, up ~28% YoY Analyst consensus: Majority rating average 12-month price target between ₹1,650–1,750, with a long-term upside potential in the ₹2,200–2,400 range based on peer comparisons and technical projections. Investment Outlook & Strategy Short-Term (6–12 months): Positive momentum expected as US generics recover and chronic therapies maintain growth; could reach ₹1,650–1,760. Medium-Term (1–3 years): Pipeline monetization, stable margins, acquisitions (cosmetics, international assets) drive EPS growth toward ₹2,000+. Long-Term (3–5 years): Transition to higher-value therapeutics and specialty generics may unlock ₹2,200–2,400 valuation, offering ~60% upside from today.